Biomarin Pharmaceutical
Clinical trials sponsored by Biomarin Pharmaceutical, explained in plain language.
-
Can a common arthritis drug make PKU treatment safer and more effective?
Disease control Recruiting nowThis study tests whether adding methotrexate (a drug that calms the immune system) can help adults with PKU tolerate and respond better to Palynziq, a protein-based treatment. About 12 adults who either haven't taken Palynziq before or have high blood Phe levels despite treatment…
Phase: PHASE4 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to boost height in kids with dwarfism
Disease control Recruiting nowThis study tests a new medicine called BMN 333 against an existing drug (vosoritide) to see if it can safely improve growth in children with achondroplasia, the most common form of dwarfism. About 160 children aged 2 to 17 will take part. The goal is to measure how much they grow…
Phase: PHASE2, PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for short kids: experimental drug takes on growth hormone
Disease control Recruiting nowThis study tests a drug called vosoritide in 100 children with idiopathic short stature (short height with no known cause). The goal is to see if vosoritide can safely improve growth compared to standard growth hormone. Participants will receive either vosoritide or growth hormon…
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to boost growth in kids with noonan syndrome
Disease control Recruiting nowThis study tests vosoritide, a protein that stimulates bone growth, in 30 children with Noonan syndrome who are not growing well despite growth hormone treatment. The goal is to see if vosoritide can safely increase their growth rate over six months. Participants will receive one…
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for babies with rare dwarfism: daily shot may boost growth
Disease control Recruiting nowThis study tests a daily injection called vosoritide in infants and toddlers (0 to 3 years old) with hypochondroplasia, a genetic condition that causes short stature. The goal is to see if the drug safely improves growth over 52 weeks. About 60 children will receive either vosori…
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
10-Year study to track immune risks of PKU drug
Disease control Recruiting nowThis 10-year study will follow 200 people with PKU who are taking or about to start Pegvaliase (Palynziq). Researchers will monitor immune reactions, inflammation, and lab results to better understand long-term safety. The goal is to improve management of side effects like allerg…
Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
10-Year study tracks safety of PKU drug palynziq
Disease control Recruiting nowThis 10-year observational study is following 450 people with PKU who are taking or starting pegvaliase (Palynziq) to monitor long-term safety, especially allergic reactions. Researchers are tracking serious side effects like anaphylaxis, severe joint pain, and low phenylalanine …
Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New study uses virtual tools to track achondroplasia over time
Knowledge-focused Recruiting nowThis study observes about 170 children and adults with achondroplasia in the United States over roughly 5 years. Researchers will collect health records and questionnaires to track growth, medical issues, surgeries, and quality of life. The goal is to better understand the condit…
Sponsor: BioMarin Pharmaceutical • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to unlock growth secrets in short children
Knowledge-focused Recruiting nowThis study will follow 300 children with idiopathic short stature (ISS) — meaning they are shorter than expected for no known medical reason. Researchers will measure their height, weight, and other health factors over time to create a detailed picture of natural growth. The goal…
Sponsor: BioMarin Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New study tracks PKU drug palynziq in pregnancy: what are the risks?
Knowledge-focused Recruiting nowThis study follows 50 pregnant women with phenylketonuria (PKU) who have taken the drug Palynziq (pegvaliase) around the time of pregnancy or while breastfeeding. Researchers will track pregnancy outcomes and infant health, including birth defects and development. The goal is to …
Sponsor: BioMarin Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC